和黄医药 HCM
$15.16 +$0.96 (+6.76%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $15.16 0.00%
开盘$14.44
昨收$14.20
当日区间$14.44 – $15.31
成交量157.3K
市值$2.64B
市盈率（TTM）189.5
股息率–
HCM 相关新闻
匹配 Hutchmed (China) 或代码 HCM 的头条新闻，按最新排序。
- CICC: Maintains "Outperform" rating for Hutchmed (00013), raises target price to HK$28 正面
- Daiwa upgrades HUTCHMED (00013.HK) to “Buy,” raising target price to HK$28.5 正面
- Hutchmed (China) Target Price Raised to HK$39.00 From HK$36.00 by Citi Research 0013.HK 正面
- Hutchmed (00013.HK) announced that it has entered into a licensing agreement with GlaxoSmithKline for a KRAS-EGFR antibody-drug conjugate cancer therapy.
- Hutchmed (0013.HK): ATTC licensing to GSK clarifies overseas expansion path 正面
- Hutchmed (00013.HK) announced the submission of a New Drug Application (NDA) in the United States for the combination of ORPATHYS and TAGRISSO for the treatment of MET-driven EGFR-mutated lung cancer.
- BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Raises Target Price to $18 正面
- Hutchmed (0013.HK): The innovative drug segment posted a steady recovery in 1H26, with a flurry of catalysts expected in 2H26–2027; target price raised. 正面
- Hutchmed (00013.HK): The SAFFRON global Phase III study of savolitinib has yielded positive results, potentially accelerating its global regulatory submissions.
- Hutchmed (00013.HK): SAFFRON Success—Promising Prospects for Savolitinib's Overseas Regulatory Submission
- BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $17 负面
- Goldman Sachs Maintains Hutchmed (China)(HCM.US) With Hold Rating, Cuts Target Price to $14 负面
- BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $20
- Morgan Stanley Upgrades Hutchmed (China)(HCM.US) to Hold Rating, Cuts Target Price to $13.6 中性
- BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Cuts Target Price to $21 负面
暂无评论——快来第一个聊聊 HCM。
登录后参与讨论。